ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AVCT Avacta Group Plc

45.00
-0.30 (-0.66%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -0.66% 45.00 44.50 45.50 45.25 44.25 45.25 2,905,504 16:28:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -3.26 127.63M
Avacta Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 45.30p. Over the last year, Avacta shares have traded in a share price range of 43.25p to 166.50p.

Avacta currently has 283,614,110 shares in issue. The market capitalisation of Avacta is £127.63 million. Avacta has a price to earnings ratio (PE ratio) of -3.26.

Avacta Share Discussion Threads

Showing 3226 to 3247 of 79775 messages
Chat Pages: Latest  131  130  129  128  127  126  125  124  123  122  121  120  Older
DateSubjectAuthorDiscuss
08/10/2018
15:11
Thanks Timbo
1i1i1i
08/10/2018
12:18
Slides and video from the recent TPI investor evening are here:


Good questions at the end 😉

timbo003
05/10/2018
08:25
I was at the Proactive investor meeting last night and was impressed by the presentation. I was already a shareholder as a result of the recent fund raising but hadn't really looked into the technology as much as I should have done. There are various aspects of the affimer platform which are advantageous. For example the fact that the structure gets around the antibody IP mean that this technology can be used in a variety of beneficial ways commercially. In addition the fact that the reagents used in the diagnostic area are plant based means it is distinctly separate from the therapeutic products.

Plus the company is clearly focused on getting deals in the short term. The CEO said a diagnostics deal is imminent and others will follow. And the company is funded into 2020 and that doesn't include any deals in the interim. The key time will be when they get to the first in human studies which will be Q1 next year with the PDL1-LAGS bispecific.

Yes I have bought some more this morning via spreadbet....

Nobby

nobbygnome
02/10/2018
14:28
Yep
Academic CEO's don't you just love them!

lantanatony
02/10/2018
14:18
Unbelievable turnover more or less the same but losses have gone up to £8.83 million. This is over three times the turnover. How many more new share issues can they have?
poacher45
25/9/2018
12:14
results next week ... too much to hope for update on deals or collaborations
the drewster
25/9/2018
11:46
Looks like it's heading back upwards. All I can get online is 15k at 25.68p
dave4545
24/9/2018
21:52
Well in theory you shouldn’t get more than is in public domain other than sight of whites of their eyes!
bscuit
24/9/2018
17:18
Well,No need to go to this one as it will be the same old stuff!
lantanatony
24/9/2018
12:00
I was one of 3 PIs that attended the last dedicated investor event at fincap.
the drewster
24/9/2018
11:15
I will be there!
nobbygnome
24/9/2018
10:58
Avacta will be presenting to investors at the upcoming Proactive One2One Forum on 4th October in London. Details here:
aim_trader
11/9/2018
11:55
83k sold for 24.75p when 26p bid !

Nice profit for the mm who took that

dave4545
10/9/2018
08:12
27.8p full offer paid for 20k

Strange as a 20k dummy buy here is 27.25p online

dave4545
07/9/2018
23:02
I have just seen Alistair Smith on LSE interview.
It's the same old jam tomorrow stuff.
In fact it is a disgrace saying that shareholders should only consider Avacta as a new company!
Because it's only had the Affimer technology for a few years.
Well what about the long-term investors that were sold a pup.
This company is not worthy.

lantanatony
05/9/2018
21:00
Company for sale.
Great potential.

Other management needed who can add the value and steal the company!!

escapetohome
05/9/2018
20:58
Yep
Hardman just a rehash of all gone before !
It seem Avacta have nothing more to say.
It seems just a conduit to pay the Directors.
And I forgot to mention the Brokers and other professionals.

lantanatony
05/9/2018
17:14
Hardman note is Hardly informative
toffeeman
05/9/2018
12:26
Hardman & Co. note out today on Avacta.
mortimer7
05/9/2018
00:26
Look at the Novartis news overnight Each treatment costs $ 475,000
hampton58
03/9/2018
23:19
The planet that you are on would help...
ffp
03/9/2018
18:59
Another excellent volume day and simmering nicely,....GL S
swizz
Chat Pages: Latest  131  130  129  128  127  126  125  124  123  122  121  120  Older

Your Recent History

Delayed Upgrade Clock